A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study

BACKGROUND: Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some patients with chronic myeloid leukaemia (CML) with deep molecular responses, defined as stable MR4 (BCR-ABL1/ABL1 ratio <0.01%). However, patients in stable major molecular response (MMR; MR3; BCR-ABL1/ABL...

Full description

Bibliographic Details
Main Authors: Clark, Richard E., Polydoros, Fotios, Apperley, Jane F., Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L., de Lavallade, Hugues, O'Brien, Stephen G., Coffey, Tony, Foroni, Letizia, Copland, Mhairi
Format: Article
Published: Elsevier 2017
Subjects:
chronic myeloid leukaemia
tyrosine kinase inhibitors
stopping treatment
imatinib
nilotinib
dasatinib
Online Access:https://eprints.nottingham.ac.uk/48671/

Internet

https://eprints.nottingham.ac.uk/48671/

Similar Items